Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycopyrrolate Dose Finding with BDP/FF in COPD
NCT01476813Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Mar 2012
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glycopyrronium in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Area under curve FEV1 0-12h at Day 7. Started Mar 2012; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01476813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01476813.